Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Goodin

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 21, 1999
Survey of multiple sclerosis in northern California. Northern California MS Study GroupD S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 5, 1998
A questionnaire to assess neurological impairment in multiple sclerosisD S Goodin
Electroencephalography and Clinical Neurophysiology|July 1, 1990
Clinical utility of long latency 'cognitive' event-related potentials (P3): the prosD S Goodin
Biological Psychiatry|October 1, 1986
P300 latency as a biologic marker of dementiaD S Goodin
Journal of Neurology|July 18, 2006
Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centreD S Goodin
Neuroepidemiology|February 2, 2000
The cladribine trial in secondary progressive MS: responseD S Goodin
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic developments in multiple sclerosisD S Goodin
Neurology|July 1, 1991
The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical reviewD S Goodin
Neurologic Clinics|August 1, 1985
Electrophysiologic evaluation of dementiaD S Goodin
International MS Journal|January 21, 2006
Evidence-based medicineD S Goodin
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 21, 1999
Survey of multiple sclerosis in northern California. Northern California MS Study GroupD S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 5, 1998
A questionnaire to assess neurological impairment in multiple sclerosisD S Goodin
Electroencephalography and Clinical Neurophysiology|July 1, 1990
Clinical utility of long latency 'cognitive' event-related potentials (P3): the prosD S Goodin
Biological Psychiatry|October 1, 1986
P300 latency as a biologic marker of dementiaD S Goodin
Journal of Neurology|July 18, 2006
Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centreD S Goodin
Neuroepidemiology|February 2, 2000
The cladribine trial in secondary progressive MS: responseD S Goodin
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic developments in multiple sclerosisD S Goodin
Neurology|July 1, 1991
The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical reviewD S Goodin
Neurologic Clinics|August 1, 1985
Electrophysiologic evaluation of dementiaD S Goodin
International MS Journal|January 21, 2006
Evidence-based medicineD S Goodin
Pageof 11